



ASX / Media Release

July 15 2013

CIRCADIAN MOVES TO NEW SOUTH YARRA OFFICE

Circadian Technologies Limited (ASX.CIR; OTCQX:CKDXY) have relocated from Level 1, 10 Wallace Avenue, Toorak Victoria 3142, Australia.

Effective Monday 15 July 2013, our new office location will be Suite 0403, Level 4, 650 Chapel Street, South Yarra Victoria 3141, Australia. Our office numbers and email addresses will remain the same.

:

Steven Zammit
Company Secretary
Tel: +61 (0) 3 9826 0399
steven.zammit@circadian.com.au

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer through its subsidiary Ceres Oncology, as well as developing VGX-300 (soluble VEGFR-3) for 'back of the eye' disease such as "wet" Age Related Macular Degeneration through its subsidiary Opthea. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.